QUICK ANSWER · AEO / GEO
An experimental ERR agonist with preclinical-only evidence; animal exercise-mimetic findings do not establish human benefit.
ENTITY FACTS
What should readers identify first?
What remains unknown?
- human pharmacokinetics, bioavailability and target engagement
- safe exposure range and short- or long-term adverse effects in humans
- whether mouse endurance and metabolic findings translate to people
- comparability between published research material and products offered online
- current product-specific status in Thailand, the United States, European Union and United Kingdom
- case-specific anti-doping classification and analytical thresholds
What limits these conclusions?
- The core efficacy literature consists of cell and mouse studies from a limited research lineage. Human-derived cell work does not establish exposure, efficacy or safety in a person. No verified clinical administration dataset means an evidence grade above E is not justified. Later work on SLU-PP-915 is about a different molecule and cannot be transferred to SLU-PP-332.
This overview does not replace the detailed adverse-event and product-specific risk discussion in the complete Thai profile or the original sources.
EVIDENCE BOUNDARY
What this overview does not establish
- An evidence grade does not rank this molecule against another treatment.
- A molecule name does not establish the identity, purity or regulatory status of a product.
- Animal, cell or biomarker findings do not automatically establish human clinical benefit.
- Approval in one country or indication does not transfer globally.
Where can I check the evidence?
Original sources from the same evidence record used by Compare. Read each source's population, methods, limitations and date; a citation is not product endorsement.
- https://pertento.fda.moph.go.th/FDA_SEARCH_DRUG/SEARCH_DRUG/FRM_SEARCH_DRUG.aspx
- https://www.accessdata.fda.gov/scripts/cder/daf/
- https://clinicaltrials.gov/search?term=%22SLU-PP-332%22
- https://www.ema.europa.eu/en/medicines/download-medicine-data
- https://pubmed.ncbi.nlm.nih.gov/36988910/
- https://pubmed.ncbi.nlm.nih.gov/37739806/
- https://pubmed.ncbi.nlm.nih.gov/40692696/
- https://pubmed.ncbi.nlm.nih.gov/41688415/
- https://pubmed.ncbi.nlm.nih.gov/41421047/
- https://www.wada-ama.org/en/resources/world-anti-doping-program/prohibited-list
- https://www.wada-ama.org/sites/default/files/2025-09/2026list_en_final_clean_september_2025.pdf
- https://products.mhra.gov.uk/
FAQ · ANSWER ENGINE
Frequently asked questions
What is SLU-PP-332?
SLU-PP-332 is described pharmacologically as Experimental small-molecule ERRα/β/γ agonist; not a peptide. An experimental ERR agonist with preclinical-only evidence; animal exercise-mimetic findings do not establish human benefit.
Does SLU-PP-332 have strong evidence?
PrimeCoreBio records Evidence Grade E. This grade describes evidence strength, not comparative effectiveness or suitability for an individual.
Is SLU-PP-332 approved everywhere?
No global conclusion should be inferred. PrimeCore Class C must be read with the exact product, country and indication on the source-rich profile.
Educational information only. This page does not provide diagnosis, treatment, prescribing, dosage, injection instructions or individual medical advice.